Abstract
The membrane inhibitor of reactive lysis (MIRL, CD59) is an 18 kDa glycosyl phosphatidylinositol-anchored membrane glycoprotein that inhibits complement-mediated lysis, at least in part by restricting the formation of the membrane attack complex (MAC). MIRL is expressed by all peripheral blood hematopoietic cells, by endothelial cells, and by some cellular elements of the peripheral and central nervous systems. The erythrocytes of paroxysmal nocturnal hemoglobinuria (PNH) are deficient in MIRL, and the enhanced susceptibility of PNH erythrocytes to complement-mediated lysis is due primarily to this deficiency.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Davies A, Simmons DL, Hale G, Harrison RA, Tighe H, Lachmann PJ, Waldmann H (1989) CD59, an Ly-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J.Exp Med 170: 637–654
Davitz MA, Low MG, Nussenzweig V (1986) Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC): selective modification of a complement regulatory protein. J Exp Med 163: 1150–1161
Ezzell JL, Wilcox LA, Bernshaw NJ, Parker CJ (1991) Induction of the paroxysmal nocturnal hemoglubinuria phenotype in normal human erythrocytes. Blood (in press)
Groux H, Huet S, Aubrit F, Tran HC, Boumsell L, Bernard A (1989) A 19-kDa human erythrocyte molecule H19 is involved in rosettes, present on nucleated cells, and required for T cell activation. J Immunol 142: 3013–3020
Hamilton KK, Ji A, Rollins S, Stewart BH, Sims PJ (1990) Regulatory control of the terminal complement proteins at the surface of human endothelial cells: neutralization of a C5b-9 inhibitor by antibody to CD59. Blood 76: 2572–2577
Hänsch GM, Hammer CH, Vanguri P, Shin ML (1981) Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci USA 78: 5118–5121
Hänsch GM, Schönermark S, Roelcke D (1987) Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9. J Clin Invest 80: 7–12
Harada R, Okada N, Fujita T, Okada H (1990) Purification of 1F5 antigen that prevents complement attack on homologous cell membranes. J Immunol 144: 1823–1828
Hideshima T, Okada N, Okada H (1990) Expression of HRF20, a regulatory molecule of complement activation, on peripheral blood mononuclear cells. Immunology 69: 396–401
Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ (1989a) Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 84: 7–17
Holguin MH, Wilcox LA, Bernshaw NJ, Rosse WF, Parker CJ (1989b) Erythrocyte membrane inhibitor of reactive lysis: effects of phosphatidylinositol-specific phospholipase C on the isolated and cell-associated protein. Blood 75: 284–289
Holguin MH, Wilcox LA, Bernshaw NJ, Rosse WF, Parker CJ (1990) Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. J Clin Invest 84: 1387–1394
Hu V, Shin ML (1984) Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9. J Immunol 133: 2133–2137
Kinoshita T, Medof ME, Silber R, Nussenzweig V (1985) Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients and paroxysmal nocturnal hemoglobinuria. J Exp Med 162: 75–92
Lachmann PJ, Halbwachs L (1975) The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol 21: 109–114
Lichtenheld MG, Olsen KJ, Lu P, Lowrey D, Hameed A, Hengartner H, Podack ER (1988) Structure and function of human perforin. Nature 335: 448–451
Logue GL, Rosse WF, Adams JP (1973) Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest 52: 1129–1137
Malek TR, Ortega G, Chan C, Kroczek R, Shevach EM (1986) Role of Ly-6 in T cell activation. III. Induction of T cell activation by monoclonal anti-Ly-6 antibodies. J Exp Med 164: 709–722
McGeer PL, Walker DG, Akiyama H, Kawamata T, Guan AL, Parker CJ, Okada N, McGeer EG (1991) Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain. Brain Res (in press)
Medof ME, Kinoshita T, Nussenzweig V (1984) Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 160: 1558–1578
Medof ME, Kinoshita T, Silber R, Nussenzweig V (1985) Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor. Proc Natl Acad Sci USA 82: 2980–2984
Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V (1986) Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 165: 848–864
Medof ME, Gottlieb A, Kinoshita T, Hall S, Silber R, Nussenzweig V, Rosse WF (1987) Relationship between decay accelerating factor deficiency, acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest 80: 165–174
Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ (1990a) Human protectin (CD59), an 18–20 kD complement lysis restricting factor, inhibits C5b-8 catalyzed insertion of C9 into lipid bilayers. Immunology 72: 1–9
Meri S, Morgan BP, Wing M, Jones J, Davies A, Podack E, Lachmann PJ (1990b) Human protectin (CD59), an 18–20-KD homologous complement restriction factor, does not restrict perforin-mediated lysis. J Exp Med 172: 367–370
Nicholson-Weller A, Zaia J, Raum MG, Coligan JE (1986) Decay accelerating factor (DAF) peptide sequences share homology with a consensus sequence found in the superfamily of structurally related complement proteins including haptoglobin, factor XIII, B2-glycoprotein I, and the IL-2 receptor. Immunol Lett 14: 307–311
Nose M, Katoh M, Okada N, Kyogoku M, Okada H (1990) Tissue distribution of HRF20, a novel factor preventing the membrane attack of homologous complement, and its predominant expression on endothelial cells in vivo. Immunology 70: 145–149
Okada N, Harada R, Fujita T, Okada H (1989a) A novel membrane glycoprotein capable of inhibiting membrane attack by homologous complement. Int Immunol 1: 205–208
Okada H, Nagami Y, Takahashi K, Okada N, Hideshima T, Takizawa H, Kondo J (1989b) 20 kDa homologous restriction factor of complement resembles T cell activating protein. Biochem Biophys Res Commun 162: 1553–1559
Okada N, Harada R, Fujita T, Okada H (1989c) Monoclonal antibodies capable of causing hemolysis of neuraminidase-treated human erythrocytes by homologous complement. J Immunol 143: 2262–2266
Packman CH, Rosenfeld SI, Jenkins DE, Thiem PA, Leddy JP (1979) Complement lysis of human erythrocytes: differing susceptibility of 2 types of paroxysmal nocturnal hemoglobinuria cells to C5b-9. J Clin Invest 64: 428–433
Palfree RGE, Sirlin S, Dumont FJ, Hämmerling U (1988) N-terminal and cDNA characterization of murine lymphocyte antigen Ly-6C.2. J Immunol 140: 305–310
Parker CJ, Wiedmer T, Sims PJ, Rosse WF (1985) Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest 75: 2074–2084
Parker CJ, Stone OL, Bernshaw NJ (1989) Characterization of the enhanced susceptibility of paroxysmal nocturnal hemoglobinuria erythrocytes to complement-mediated hemolysis initiated by cobra venom factor. J Immunol 142: 208–216
Rathoff WD, Knez JJ, Prince GM, Medof ME (1990) Structural properties of the glycoplasmanylinositol anchor structure of the complement membrane attack complex inhibitor CD59. Blood 76: 389a
Reiser H, Oettgen H, Yeh ETH, Terhorst C, Low MG, Benacerraf B, Rock KL (1986) Structural characterization of the TAP molecule: a phosphatidylinositol-linked glycoprotein distinct from the T cell receptor/T3 complex and Thy-1. Cell 47: 365–370
Roberts WL, Kim BH, Rosenberry TL (1987) Differences in the glycolipid membrane anchors of bovine and human erythrocyte acetylcholinesterases. Proc Natl Acad Sci USA 84: 7817–7821
Roberts WL, Myher JJ, Kuksis A, Low MG, Rosenberry TL (1988) Lipid analysis of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase. J Biol Chem 263: 18766–18775
Rock KL, Yeh ETH, Gramm CF, Haber SI, Reiser H, Benacerraf B (1986) TAP, a novel T cell-activating protein involved in the stimulation of MHC-restricted T lymphocytes. J Exp Med 163: 315–333
Rollins SA, Sims PJ (1990) The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J Immunol 144: 3478–3483
Rollins SA, Zhao Jl, Ninomiya H, Sims PJ (1991) Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-89 or C9 within C5b-9. J Immunol 146: 2345–2351
Rosenfeld SI, Packman CH, Jenkins DE, Countryman JK, Leddy JP (1980) Complement lysis of human erythrocytes III. Differing effectiveness of human and guinea pig C9 on normal and paroxysmal nocturnal hemoglobinuria cells. J Immunol 125: 2063–2068
Rosse WF, Parker CJ (1985) Paroxysmal nocturnal hemoglobinuria. Clin Haematol 14: 105–125
Rosse WF, Hall S, Campbell M, Borowitz M, Moore JO, Parker CJ (1991) The erythrocytes in paroxysmal nocturnal hemoglobinuria of intermediate sensitivity to complement lysis (to be published)
Schönermark S, Rauterberg EW, Shin ML, Loke S, Roelcke D, Hänsch GM (1986) Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 136: 1772–1776
Selvaraj P, Dustin ML, Silber R, Low MG, Springer TA (1987) Deficiency of lymphocyte function- associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. J Exp Med 166: 1011–1025
Sims PJ, Rollins SA, Wiedmer T (1989) Regulatory control of complement on blood platelets. Modulation of platelet procoagulant responses by a membrane inhibitor of the C5b-9 complex. J Biol Chem 264: 19228–19235
Sirchia G, Dacie JV (1967) Immune lysis of AET-treated normal red cells (PNH-like cells). Nature 215: 747–748
Sirchia G, Ferrone S, Mercuriali F (1965) The action of two sulfhydryl compounds on normal human red cells: relationship to red cells of paroxysmal nocturnal hemoglobinuria. Blood 25: 502–509
Stefanova I, Hilgert I, Kristofova H, Brown R, Low MG, Horejsi V (1989) Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phos-phatidylinositol. Mol Immunol 26: 153–161
Sugita Y, Nakano Y, Tomita M (1988) Isolation from human erythrocytes of a new membrane protein which inhibits the formation of complement transmembrane channels. J Biochem 104: 633–637
Sugita Y, Tobe T, Oda E, Tomita M, Yasukawa K, Yamaji N, Takemoto T, Furuichi K, Takayama M, Yano S (1989a) Molecular cloning and characterization of MACIF, an inhibitor of membrane channel formation of complement. J Biochem 106: 555–557
Sugita Y, Mazda T, Tomita M (1989b) Amino-terminal amino acid sequence and chemical and functional properties of a membrane attack complex-inhibitory factor from human erythrocyte membranes. J Biochem 106: 589–592
Telen MJ, Green AM (1989) The INAB phenotype: characterization of the membrane protein and complement regulatory defect. Blood 74: 437–441
Telen MJ, Hall SE, Green AM, Moulds JJ, Rosse WF (1988) Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. J Exp Med 167: 1993–1998
Tschopp J, Masson D, Stanley KK (1986) Structural/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis. Nature 322: 831–834
Vogel C-W, Müller-Eberhard HJ (1982) The cobra venom factor-dependent C3 convertase of human complement. J Biol Chem 257: 8292–8299
Vogel C-W, Smith CA, Müller-Eberhard HJ (1984) Cobra venom factor: structural homology with the third component of human complement. J Immunol 133: 3235–3241
Whitlow MB, Iida K, Stefanova I, Bernard A, Nussenzweig V (1990) H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement. Cell Immunol 126: 176–184
Wilcox LA, Ezzell JL, Bernshaw NJ, Parker CJ (1991) Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum. Blood (in press)
Yamamoto K (1977) Lytic activity of C5–9 complexes for erythrocytes from the species other than sheep: C9 rather than C8-dependent variation in lytic activity. J Immunol 119: 1482–1485
Yamashina M, Ueda E, Kinoshita T, Takami T, Ojima A, Ono H, Tanaka H, Kondo N, Orii T, Okada N, Okada H, Inoue K, Kitani T (1990) Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J Med 323: 1184–1189
Yeh ETH, Reiser H, Daley J, Rock KL (1987) Stimulation of T cells via the TAP molecule, a member in a family of activating proteins encoded in the Ly-6 locus. J Immunol 138: 91–97
Yeh ETH, Reiser H, Bamezai A, Rock KL (1988) TAP transcription and phosphatidylinositol linkage mutants are defective in activation through the T cell receptor. Cell 52: 665–674
Young JD-E, Cohn ZA, Podack ER (1986) The ninth component of human complement and the poreforming protein perforin 1 from cytotoxic T cells: structural, immunological and functional similarities. Science 233: 184–190
Zalman LS, Wood LM, Müller-Eberhard HJ (1986) Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologous complement transmembrane channels. Proc Natl Acad Sci USA 83: 6975–6979
Zalman LS, Wood LM, Frank MM, Müller-Eberhard HJ (1987) Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria. J Exp Med 165: 572–577
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Holguin, M.H., Parker, C.J. (1992). Membrane Inhibitor of Reactive Lysis. In: Parker, C.J. (eds) Membrane Defenses Against Attack by Complement and Perforins. Current Topics in Microbiology and Immunology, vol 178. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-77014-2_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-77014-2_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-77016-6
Online ISBN: 978-3-642-77014-2
eBook Packages: Springer Book Archive